{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:21:17Z","timestamp":1788621677644,"version":"build-2803163510"},"reference-count":19,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>&lt;p&gt;Introduction: Anemia can influence decisions regarding initiation, dosing, and discontinuation of Janus kinase inhibitor therapy for myelofibrosis. We evaluated the impact of new-onset or worsening anemia following ruxolitinib initiation on spleen response, symptom severity, and overall survival in patients with myelofibrosis. Methods: This post hoc analysis used data from all patients enrolled in the phase 3b JUMP trial. Outcomes were stratified by presence or absence of new-onset or worsening anemia following ruxolitinib initiation, defined as hemoglobin decrease \u226515 g\/L from baseline and hemoglobin &lt;100 g\/L (female)\/&lt;110 g\/L (male) at Week 12, new transfusion requirement post-baseline until Week 12 (for baseline non\u2013transfusion-dependent patients), or \u226550% increase from baseline in red blood cell transfusions through Week 12. Results: Overall, 2,233 patients were included; 52.9% developed new-onset or worsening anemia up to Week 12. Ruxolitinib was associated with improvements in spleen length and myelofibrosis symptoms, regardless of the presence or absence of new-onset or worsening anemia or baseline anemia status. No differences in spleen response or overall survival were observed between patients with versus without new-onset or worsening anemia, regardless of baseline anemia status. Conclusions: These results support the use of ruxolitinib in patients with myelofibrosis, regardless of baseline anemia or development of treatment-related anemia. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000546585","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T16:02:20Z","timestamp":1752336140000},"page":"363-372","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study"],"prefix":"10.1159","volume":"149","author":[{"given":"Haifa Kathrin","family":"Al-Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Hamer-Maansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050984"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151449"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26129"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554634"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.022"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090299"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0527-7"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16462"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1146950"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006889"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000279"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025802"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000546585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:02:22Z","timestamp":1779984142000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000546585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,5,28]]}},"URL":"https:\/\/doi.org\/10.1159\/000546585","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.29551841","asserted-by":"subject"}]},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}